Augtyro™
AUGTYRO (repotrectinib) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Therapy Area: Oncology
Rezzayo™
REZZAYO (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
Therapy Area: Antifungal
Relyvrio®
RELYVRIO (sodium phenylbutyrate and taurursodiol) is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.
Therapy Area: Neurodegenerative Disease
Spevigo®
PEVIGO (spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis flares in adults.
Therapy Area: Dermatology
Amvuttra™
AMVUTTRA (vutrisiran) injection is a transthyretin-directed small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Therapy Area: Rare Disease
Pyrukynd®
PYRUKYND (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Therapy Area: Blood Disorders
Camcevi®
CAMCEVI (leuprolide) 42 mg subcutaneous injection is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer. CAMCEVI is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or the components of CAMCEVI.
Therapy Area: Oncology
Cabometyx®
CABOMETYX (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC) and patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Therapy Area: Oncology
Orgovyx™
ORGOVYX (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Therapy Area: Prostate Cancer
Gemtesa®
GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Therapy Area: Urinary
Oxlumo™
OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Therapy Area: Rare Disease
Veklury®
VEKLURY (remdesivir) is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. VEKLURY should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.
